Lévodopa/Bensérazide Teva

Levodopa/Benserazide, the active ingredient in Lévodopa/Bensérazide Teva, is an antiparkinson agent presented as an oral tablet for oral use. It treats Parkinson's disease by restoring dopamine activity in the central nervous system of adult patients. The combination of levodopa with benserazide enhances central availability while minimizing peripheral side effects, making it a cornerstone of symptomatic management.

GNH USA supplies Lévodopa/Bensérazide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Levodopa/Benserazide is used in the management of Parkinsonian disorders, targeting dopaminergic deficiency.

- Parkinson's disease: reduces bradykinesia, rigidity and tremor, improving motor function. - Drug‑induced Parkinsonian syndrome: alleviates motor deficits caused by dopamine‑blocking antipsychotics. - Secondary parkinsonism due to cerebrovascular disease: helps control motor symptoms when dopaminergic loss is present.

Levodopa/Benserazide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Vomiting: occasional emesis, especially at treatment initiation. - Orthostatic hypotension: dizziness upon standing due to peripheral vasodilation. - Dyskinesia: involuntary movements that may develop with chronic therapy.

Serious or Rare Side Effects: - Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction with high fever and rigidity. - Cardiac arrhythmias: uncommon but may occur, requiring monitoring.

Levodopa/Benserazide requires careful clinical monitoring and patient education.

- Dose titration: start with a low dose and increase gradually under medical supervision. - Psychiatric monitoring: watch for hallucinations, confusion or mood changes. - Avoid abrupt discontinuation: sudden stop may precipitate severe withdrawal symptoms. - Renal/hepatic impairment: consider dose adjustment or increased monitoring. - Concomitant MAO‑B inhibitors: risk of hypertensive crisis; assess benefit‑risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levodopa/Benserazide interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may precipitate hypertensive crisis. - Anticholinergic agents: can mask motor side effects and worsen confusion. - CNS depressants (e.g., barbiturates): reduce levodopa efficacy. - High‑protein meals: decrease levodopa absorption, reducing therapeutic effect.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors (e.g., selegiline): may enhance dopaminergic activity and increase side‑effect risk. - Antipsychotics (e.g., haloperidol): antagonize dopamine receptors, diminishing drug benefit. - Iron or calcium supplements: can bind levodopa in the gut and lower its bioavailability.